We are a patient-driven organization, dedicated to improving the life expectancy & quality of life for ALK-positive cancer patients worldwide. #StrongerTogether
United States
Joined May 2018
- Tweets3.8K
- Following914
- Followers2.9K
- Likes6K
ALK Positive is honored to contribute $50,000 to the Ross Camidge, MD, PhD, Thoracic Oncology Endowed Program Support Fund.
With deep gratitude for Dr. Camidge’s lasting impact, we’re proud to support the future of thoracic oncology. buff.ly/xupfzXJ
🌍 ALK Positive is headed to #ESMO2026!
Dr. Ken Culver and Yvonne Diaz will be connecting with physicians, researchers, and global partners to advance ALK-positive cancer research and amplify patient voices worldwide.
ALK Positive retweeted
Don’t miss this joint ALKtALK from @ALKPositiveinc and @EGFRResisters with Dr @kyleconcannonMD (aka @Cracking_Cancer).
Today, Sunday 18 Oct at 7pm ET.
🔗 alkpositive.org/living-with-…
🧬 Could CAR T-cell therapy offer a new way to treat lung cancer?
Join ALK Positive & EGFR Resisters tomorrow, Oct. 18, at 7 PM ET for a special ALKtALK with Dr. Kyle Concannon exploring ACES CAR T-cell research and its potential for ALK, EGFR & other lung cancers.
ALKtALK replay is now available!
What’s new in ALK-positive cancer research, and what could it mean for you?
Dr. Ken Culver shares clinical trial updates, emerging research, and a preview of our November Lung Cancer Awareness Month campaign!
▶️ Watch: youtu.be/r3ocrSEb-jc
What does survivorship mean when living with ALK-positive cancer?
In this ALKtALK clip, @lungoncdoc shares why survivorship goes beyond treatment to include quality of life, adapting, and living well.
🎥 Watch the full replay: youtu.be/aIVlb1OiWxU
#ALKPositive #ALKtALK
How could we find new cancer treatments faster?
ALK Positive helped fund researchers at @BIDMChealth @DanaFarber & more to help immune cells attack cancer. Early results are in lymphoma; the approach is now being explored in #lungcancer.
🔗bidmc.org/news-stories/all-n…
#LCSM
ALK Positive retweeted
What does progress in #lungcancer mean for everyday life? Why do patient voices matter in research?
Our Chair & @ALKPositiveinc BoD @Yvonne_Diaz_ & @DrYolaOLO discuss this & more from #WCLC26 in a takeover of @IASLC’s Lung Cancer Considered podcast.
🎧 bit.ly/3TA4gv3
🔬 What’s next in ALK-positive cancer research?
Join us Sunday, Oct. 4 at 7 PM ET for ALKtALK with Dr. Ken Culver, featuring updates on emerging research, clinical trials, the Global ALK Alliance + an early preview of Lung Cancer Awareness Month.
🔗 alkpositive.org/event/alktal…
ALK Positive retweeted
Proud of Dr. Ido Haimi presenting our work at @AATSHQ #ITSOS2026! Beyond local control, lung resection informed changes in care for nearly 1 in 4 patients with metastatic NSCLC in our cohort. Surgery provides tissue that can guide what comes next.
ALKtALK Season 7 premieres Sunday, Sept. 27 at 7 p.m. ET with Dr. Eric Singhi @lungoncdoc of MD Anderson. Join us on Zoom for WCLC updates, practical information for life with ALK-positive cancer, and live Q&A.
alkpositive.org/event/alktal…
#ALKtALK #ALKPositive
ALK Positive retweeted
8yr ADAURA update
🔥 informs cure vs delay-relapse debate
👉 77% pts surv data
Overall:
8yr OS 79 v 64% HR 0.52
II-IIIA:
8yr OS 74 v 58% HR 0.53
🤔
Durable OS benefit ➡️ cure for some, albeit not for all
❓optimal Osi duration
❓risk stratification w MRD
❓sequencing
#WCLC26
ALK Positive retweeted
What IS the optimal treatment for a patient with locally advanced stage IIIA NSCLC with an ALK fusion? @StephenVLiu weighs in following a thoughtful discussion at the #BTGLung2026 meeting #lcsm @Georgetown @MedStarGUH @LombardiCancer
ALK Positive retweeted
Dr @mal_itchins highlights 19 yrs of progress in ROS1 w latest data on zidesamtinib at #WCLC26. Congratulates work by @RO1ders @jfreemandaily Lilian Leigh @ProjectBreath. “12 yrs ago we didn’t test for ROS1 in Australia but thanks to a #clinicaltrial Lillian is still here today.” – at Gangnam-gu, Republic of Korea
ALK Positive retweeted
Great to see more studies & focus on our EGFR exon 20 lung cancer population w presentations by @chulkimMD @danieltanmd and Dr Lyudmila Bazhenov at #WCLC26
@JillFeldman4 challenges on why data on reduced doses is not presented. Staying on treatment is key. Panel agrees – at Gangnam-gu, Republic of Korea
ALK Positive retweeted
🆙 #WCLC26 #LCSM Mini Oral Session
🔥 A Pivotal Phase II Study of Ficonalkib, a 3rd-Generation ALK-TKI, in Advanced ALK-Positive NSCLC After 2nd-Generation ALK-TKI Failure
🎯ORR 43.1%, median PFS 9.7 mo, median DoR 15.2 mo
🎯Intracranial ORR 65.0%
🎯Most common TRAE diarrhea (71.9%); no neurologic toxicities
🎙️ Dr. Yuankai Shi
🔢 MO12.08
☑️ NCT05869162
🔗 cattendee.abstractsonline.co…
@OncoAlert @Larvol @IASLC @ALKPositiveinc
ALK Positive retweeted
Mayya had cancer progression just 9 months into treatment for ALK+ lung cancer
We celebrate advances in targeted therapies..but dont talk enough about those who progress early
Progressing early on 1 therapy doesnt mean you won’t respond well to the next
youtu.be/tgVEx4lGMzo
ALK Positive retweeted
The mRNA vaccine success vs melanoma in a Phase definitive 3 randomized trial today is on top of signs of success for personalized mRNA neoantigen vaccines vs pancreatic cancer, triple negative breast cancer, and non-small cell lung cancer wsj.com/health/pharma/modern…
ALK Positive retweeted
👀 "Thinking about these toxicities is a very different scenario than thinking about most other toxicities, because they can be so acutely harmful depending on the circumstances," said David Gerber, MD, of @UTSWMedCenter on neurocognitive tradeoffs of later-generation ALK TKIs in NSCLC.
Watch here ➡️: onclive.com/view/dr-gerber-o…
#lcsm #oncology
